U.S. markets open in 8 hours 39 minutes
  • S&P Futures

    +24.25 (+0.71%)
  • Dow Futures

    +179.00 (+0.64%)
  • Nasdaq Futures

    +76.00 (+0.65%)
  • Russell 2000 Futures

    +12.50 (+0.77%)
  • Crude Oil

    -0.18 (-0.43%)
  • Gold

    +6.80 (+0.36%)
  • Silver

    +0.27 (+1.08%)

    +0.0028 (+0.24%)
  • 10-Yr Bond

    -0.7970 (-100.00%)
  • Vix

    -29.18 (-100.00%)

    +0.0031 (+0.24%)

    -0.2000 (-0.19%)

    +1,188.66 (+10.75%)
  • CMC Crypto 200

    +7.08 (+2.96%)
  • FTSE 100

    +4.57 (+0.08%)
  • Nikkei 225

    +95.63 (+0.41%)

Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will be a featured presenter at the LD Micro Main Event on Tuesday, December 10, 2019 at 12:40 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Mr. Eiswirth will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings. In addition, his presentation will be webcast. To access the webcast, please visit http://wsw.com/ldmicro17/alim at the time of the presentation. The webcast will also be archived for 90 days and may be subsequently accessed on the Company’s website. For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.


The Company’s primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The 17 European countries include the U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands, and Luxembourg. The regulatory process is now in the national phase in which the European member states have finalized or are expected to finalize the label for the new indication to meet each country’s local requirements. Timeline to this goal varies by each country, and the non-infectious posterior uveitis indication for ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is not approved for treatment of uveitis in the United States.

For press inquiries:

For investor inquiries:

Jules Abraham

Scott Gordon

for Alimera Sciences

for Alimera Sciences